Bifogade filer
Bonesupport Q1 2024 EN
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BONESUPPORT Holding AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-04-25 08:00:00
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2024.
THE GROWTH JOURNEY CONTINUES
JANUARY – MARCH 2024
- Net sales increased by 54 percent (54 percent at constant exchange rates) and amounted to SEK 184.4 million (119.7).
- The North America (NA) segment reported a sales growth of 65 percent (65 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 27 percent (24 percent at constant exchange rates).
- The gross margin amounted to 92.6 percent (90.5).
- The operating result before effects from the Group’s incentive programs amounted to SEK 41.6 million (4.6). Reported operating result amounted to SEK 32.3 million (0.8).
- Earnings per share before and after dilution were SEK 0.33 (0.00).
"Successful regulatory milestones and continued strong growth." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- In March, the FDA announced that CERAMENT BONE VOID FILLER has been approved for use in Spine Inter Body Fusion (IBF) in the US.
- In March, the FDA announced that CERAMENT G was approved for use in open fractures in the US.
EVENTS AFTER THE REPORTING PERIOD
- Nothing to report.